Our current findings suggest the potential of tumor cell-intrinsic cGAS–STING as a novel biomarker for predicting the efficacy of immunotherapy using ICIs in GC and might provide new insights for treating patients with GC by targeting the tumor cell-intrinsic cGAS–STING pathway. The gene discussed is STING1; the disease is neoplasm.